Effect of Biological Disease-modifying Antirheumatic Drugs on Body Composition in Patients with Rheumatoid Arthritis: a Systematic Review and Meta-analysis

Overview

Journal Adv Rheumatol

Publisher Biomed Central

Specialty Rheumatology

Date 2022 May 23

PMID 35606888

Authors

Mariana Peixoto Guimaraes Ubirajara E Silva de Souza

Nathalia Sernizon Guimaraes

Maria Fernanda Brandao de Resende Guimaraes

Viviane Angelina de Souza

Adriana Maria Kakehasi

Affiliations

Soon will be listed here.

Abstract

Background: Rheumatoid arthritis (RA) generates an inflammatory profile that predisposes to total and visceral fatty accumulation and reduced fat free mass (FFM). This metabolic disorder contributes to poor functionality, increased cardiovascular risk and higher mortality. This study aimed to address a systematic review with meta-analysis to determine the effect of biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) on body composition (BC) of patients with RA.

Methods: The search was conducted at the electronic databases PubMed, Cochrane Library, Embase, Lilacs and grey literature. This investigation was carried until July 2021. Outcomes of interest were total weight, body mass index (BMI), fat mass (FM) and FFM. A meta-analysis comparing these outcomes in RA patients under bDMARD treatment versus controls was performed.

Results: Out of 137 studies reviewed, 18 were selected: fifteen prospective cohorts, two retrospective cohorts, and one cross-sectional study. The studies comprised 1221 patients, 778 on bDMARD treatment and 443 controls, which included RA patients under conventional synthetic DMARD (csDMARD). No study addressing BC analysis in patients using tsDMARD was found. The mean age and duration of the disease was 56.7 years and 6.77 years, respectively. Ten studies demonstrated a significant increase of total weight in 88.2% of patients and 42.3% for BMI. In studies that analyzed BC by double X-ray absorptiometry (DXA), the increase in total weight and BMI correlated positively to the increase in FFM. The meta-analysis carried out in five studies showed no significant difference of the mean difference for total weight 0.12 kg (95% CI - 5.58, 5.82), BMI 0.08 kg/m (95% CI - 1.76, 1.92), FM - 0.08 kg (95% IC - 5.31, 5.14), and FFM - 2.08 kg (95% CI - 7.37, 3.21).

Conclusion: This systematic review suggests a possible impact of bDMARDs on BC of RA patients, even though, the meta-analysis carried out in a small part of these studies was not able to confirm significant variation in BC components.

Trial Registration: PROSPERO code: CRD42020206949.

Citing Articles

Adipokines in Rheumatoid Arthritis: Emerging Biomarkers and Therapeutic Targets.

Bilski J, Schramm-Luc A, Szczepanik M, Mazur-Bialy A, Bonior J, Luc K Biomedicines. 2023; 11(11).

PMID: 38001998 PMC: 10669400. DOI: 10.3390/biomedicines11112998.

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.

Balsa A, Wassenberg S, Tanaka Y, Tournadre A, Orzechowski H, Rajendran V Rheumatol Ther. 2023; 10(6):1555-1574.

PMID: 37747626 PMC: 10654312. DOI: 10.1007/s40744-023-00599-1.

Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis.

Bennett J, Pratt A, Dodds R, Sayer A, Isaacs J Nat Rev Rheumatol. 2023; 19(4):239-251.

PMID: 36801919 DOI: 10.1038/s41584-023-00921-9.

Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.

Ben Tekaya A, Mehmli T, Ben Sassi M, Teyeb Z, Bouden S, Rouached L Clin Rheumatol. 2022; 42(4):979-997.

PMID: 36462127 DOI: 10.1007/s10067-022-06454-y.

References

Guimaraes M, Rodrigues C, Gomes K, Machado C, Brenol C, Krampe S . High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study. Adv Rheumatol. 2019; 59(1):44. DOI: 10.1186/s42358-019-0089-1. View

Semb A, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S . Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nat Rev Rheumatol. 2020; 16(7):361-379. DOI: 10.1038/s41584-020-0428-y. View

Challal S, Minichiello E, Boissier M, Semerano L . Cachexia and adiposity in rheumatoid arthritis. Relevance for disease management and clinical outcomes. Joint Bone Spine. 2015; 83(2):127-33. DOI: 10.1016/j.jbspin.2015.04.010. View

Engvall I, Elkan A, Tengstrand B, Cederholm T, Brismar K, Hafstrom I . Cachexia in rheumatoid arthritis is associated with inflammatory activity, physical disability, and low bioavailable insulin-like growth factor. Scand J Rheumatol. 2008; 37(5):321-8. DOI: 10.1080/03009740802055984. View

Santo R, Fernandes K, Lora P, Filippin L, Xavier R . Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2018; 9(5):816-825. PMC: 6204596. DOI: 10.1002/jcsm.12320. View

Toussirot E . Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis. Expert Opin Drug Saf. 2015; 14(4):525-32. DOI: 10.1517/14740338.2015.1007041. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021; 88:105906. DOI: 10.1016/j.ijsu.2021.105906. View

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A . Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016; 5(1):210. PMC: 5139140. DOI: 10.1186/s13643-016-0384-4. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

10.

Serelis J, Kontogianni M, Katsiougiannis S, Bletsa M, Tektonidou M, Skopouli F . Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. Clin Rheumatol. 2008; 27(6):795-7. DOI: 10.1007/s10067-008-0855-7. View

11.

Ferraz-Amaro I, Arce-Franco M, Muniz J, Lopez-Fernandez J, Hernandez-Hernandez V, Franco A . Systemic blockade of TNF-α does not improve insulin resistance in humans. Horm Metab Res. 2011; 43(11):801-8. DOI: 10.1055/s-0031-1287783. View

12.

Brown R, Spina D, Butt S, Summers G . Long-term effects of anti-tumour necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol. 2011; 31(3):455-61. DOI: 10.1007/s10067-011-1863-6. View

13.

Kopec-Medrek M, Kotulska A, Widuchowska M, Adamczak M, Wiecek A, Kucharz E . Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist. Rheumatol Int. 2011; 32(11):3383-9. PMC: 3505553. DOI: 10.1007/s00296-011-2182-6. View

14.

Toussirot E, Mourot L, Dehecq B, Wendling D, Grandclement E, Dumoulin G . TNFα blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study. Eur J Nutr. 2013; 53(3):951-61. DOI: 10.1007/s00394-013-0599-2. View

15.

Sfriso P, Caso F, Filardo G, Botsios C, Costa L, Scarpa R . Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study. Clin Rheumatol. 2016; 35(6):1615-8. DOI: 10.1007/s10067-016-3244-7. View

16.

Ramos G, Skare T, Ramos Junior O, Rabito E, Tanaami E, Stefani A . Nutritional profile of patients with chronic inflammatory diseases in the age of biologicals. Clin Rheumatol. 2018; 38(1):45-51. DOI: 10.1007/s10067-018-4085-3. View

17.

Marcora S, Chester K, Mittal G, Lemmey A, Maddison P . Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr. 2006; 84(6):1463-72. DOI: 10.1093/ajcn/84.6.1463. View

18.

van den Oever I, Baniaamam M, Simsek S, Raterman H, van Denderen J, van Eijk I . The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatol Int. 2020; 41(2):319-328. PMC: 7835149. DOI: 10.1007/s00296-020-04666-6. View

19.

Choi I, Sagawa A, Lee E, Lee E, Song Y . Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study. J Korean Med Sci. 2020; 35(22):e155. PMC: 7279943. DOI: 10.3346/jkms.2020.35.e155. View

20.

Tournadre A, Pereira B, Dutheil F, Giraud C, Courteix D, Sapin V . Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017; 8(4):639-646. PMC: 5566648. DOI: 10.1002/jcsm.12189. View